Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 20, issue 6, 2022

Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies pp. 783-792

Daniel Howdon, Sebastian Hinde, James Lomas and Matthew Franklin

Health Inequalities: To What Extent are Decision-Makers and Economic Evaluations on the Same Page? An English Case Study pp. 793-802

Sebastian Hinde, Dan Howdon, James Lomas and Matthew Franklin

Applications of Behavioral Economics to Pharmaceutical Policymaking: A Scoping Review with Implications for Best-Value Biological Medicines pp. 803-817

Yannick Vandenplas, Steven Simoens, Florian Turk, Arnold G. Vulto and Isabelle Huys

Systematic Review and Quality Assessment of Health Economic Evaluation Studies (2007–2019) Conducted in South Korea pp. 819-834

Sunghyun Yi, Jihyung Hong, Haemin Yoon, You-na Lim and Eun-Young Bae

Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance pp. 835-843

Sofie Larsson, Charlotta Edlund, Pontus Nauclér, Mikael Svensson and Anders Ternhag

Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study pp. 845-856

Ze Cong, Oth Tran, James Nelson, Monica Silver and Karen Chung

Evaluating Health Inequality in Five Caribbean Basin Countries Using EQ-5D-5L pp. 857-866

Henry H. Bailey, Mathieu F. Janssen, Fareena M. Alladin, Althea Foucade, Rodrigo Varela, Jhon A. Moreno, Marjorie Wharton, Philip Castillo and Girjanauth Boodraj

Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach pp. 867-880

Bettina Wulff Risør, Nasrin Tayyari Dehbarez, Jacob Fredsøe, Karina Dalsgaard Sørensen and Bodil Ginnerup Pedersen

Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach pp. 881-891

Silvia Moler-Zapata, Noémi Kreif, Jessica Ochalek, Andrew J. Mirelman, Mardiati Nadjib and Marc Suhrcke

Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China pp. 893-904

Ziping Ye, Raela Abduhilil, Jiaxin Huang and Lihua Sun

Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences Analysis pp. 905-917

Caroline S. Clarke, Mariya Melnychuk, Angus I. G. Ramsay, Cecilia Vindrola-Padros, Claire Levermore, Ravi Barod, Axel Bex, John Hines, Muntzer M. Mughal, Kathy Pritchard-Jones, Maxine Tran, David C. Shackley, Stephen Morris, Naomi J. Fulop and Rachael M. Hunter

Volume 20, issue 5, 2022

Including Pharmaceuticals in Bundled Payments pp. 625-628

Gerard F. Anderson, Andrew York and Joshua L. Choe

Using Economics to Impact Local Obesity Policy: Introducing the UK Centre for Economics of Obesity (CEO) pp. 629-635

Emma Frew, Nafsika Afentou, Hamideh Mohtashami Borzadaran, Paolo Candio and Irina Pokhilenko

Centralised Pharmaceutical Procurement: Learnings from Six European Countries pp. 637-650

Sabine Vogler, Eveli Bauer and Katharina Habimana

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy pp. 651-667

Christopher Sampson, Bernarda Zamora, Sam Watson, John Cairns, Kalipso Chalkidou, Patricia Cubi-Molla, Nancy Devlin, Borja García-Lorenzo, Dyfrig A. Hughes, Ashley A. Leech and Adrian Towse

UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update pp. 669-680

Laura Knight, Megan Dale, Andrew Cleves, Charlotte Pelekanou and Rhys Morris

An Economic Evaluation of Government-Funded COVID-19 Testing in Australia pp. 681-691

Jonathan Karnon, Hossein Haji Ali Afzali and Billie Bonevski

Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians pp. 693-706

Jeremy Fabes, Tuba Saygın Avşar, Jonathan Spiro, Thomas Fernandez, Helge Eilers, ·Steve Evans, Amelia Hessheimer, Paula Lorgelly and Michael Spiro

Does the Choice of Health Metric, DALY or QALY, Influence Conclusions of Health Economic Evaluation? A Case Study of Rotavirus Vaccine in Burundi pp. 707-716

Fulgence Niyibitegeka, Montarat Thavorncharoensap, Arthorn Riewpaiboon and Sitaporn Youngkong

Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers pp. 717-729

Renée E. Michels, Carlos H. Arteaga, Michel L. Peters, Ellen Kapiteijn, Carla M. L. Herpen and Marieke Krol

ENTIMOS: A Discrete Event Simulation Model for Maximising Efficiency of Infusion Suites in Centres Treating Multiple Sclerosis Patients pp. 731-742

Kristyna Lacinova, Praveen Thokala, Richard Nicholas, Pamela Dobay, Erik Scalfaro, Zuzanna Angehrn, Roisin Brennan, Ibolya Boer, Carol Lines and Nicholas Adlard

Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model pp. 743-755

Jia Liu, Xiaoning He and Jing Wu

Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland pp. 757-768

Daniel Tobias Michaeli, Mackenzie Mills and Panos Kanavos

Cost-Effectiveness and Budget Impact Analysis of Implementing a 'Soft Opt-Out' System for Kidney Donation in Australia pp. 769-779

Sameera Senanayake, Helen Healy, Steven M. McPhail, Keshwar Baboolal and Sanjeewa Kularatna

Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations pp. 781-782

Don Husereau, Michael Drummond, Federico Augustovski, Esther Bekker-Grob, Andrew H. Briggs, Chris Carswell, Lisa Caulley, Nathorn Chaiyakunapruk, Dan Greenberg, Elizabeth Loder, Josephine Mauskopf, C. Daniel Mullins, Stavros Petrou, Raoh-Fang Pwu and Sophie Staniszewska

Volume 20, issue 4, 2022

Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid? pp. 453-455

Livio Garattini and Bruno Finazzi

Data-Related Challenges in Cost-Effectiveness Analyses of Vaccines pp. 457-465

Jamison Pike, Andrew J. Leidner, Harrell Chesson, Charles Stoecker and Scott D. Grosse

Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version pp. 467-477

Eun-Young Bae, Jihyung Hong, SeungJin Bae, Seokyung Hahn, Hyonggin An, Eun-joo Hwang, Seung-min Lee and Tae-jin Lee

Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy pp. 479-486

Nadine T. Hillock, Tracy L. Merlin, John Turnidge and Jonathan Karnon

A Case Study on Reviewing Specialist Services Commissioning in Wales: TAVI for Severe Aortic Stenosis pp. 487-499

Edyta Ryczek, Susan C. Peirce, Laura Knight, Andrew Cleves, Andrew Champion, Iolo Doull and Sian Lewis

Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options pp. 501-524

Rositsa Koleva-Kolarova, James Buchanan, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten- van Mölken, László Szilberhorn, Tamás Zelei, Balázs Nagy, Sarah Wordsworth and Apostolos Tsiachristas

What Policy Approaches Were Effective in Reducing Catastrophic Health Expenditure? A Systematic Review of Studies from Multiple Countries pp. 525-541

HyunWoo Jung and Kwang-Soo Lee

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting pp. 543-555

Sara Stafford, Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis and Aiden Liu

How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15 pp. 557-572

Stephen Martin, Karl Claxton, James Lomas and Francesco Longo

Population Norms for SF-6Dv2 and EQ-5D-5L in China pp. 573-585

Shitong Xie, Jing Wu and Feng Xie

Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand pp. 587-596

Piyameth Dilokthornsakul, Ratree Sawangjit, Pisit Tangkijvanich, Maneerat Chayanupatkul, Tawesak Tanwandee, Wattana Sukeepaisarnjaroen, Pajaree Sriuttha and Unchalee Permsuwan

Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment pp. 597-607

Andrea N. Natsky, Andrew Vakulin, Ching Li Chai-Coetzer, R. Doug McEvoy, Robert J. Adams and Billingsley Kaambwa

Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women pp. 609-621

Nidhi Gupta, Dharna Gupta, Jyoti Dixit, Nikita Mehra, Ashish Singh, Manjunath Nookala Krishnamurthy, Gaurav Jyani, Kavitha Rajsekhar, Jayachandran Perumal Kalaiyarasi, Partha Sarathi Roy, Prabhat Singh Malik, Anisha Mathew, Pankaj Malhotra, Sudeep Gupta, Lalit Kumar, Amal Kataki and Shankar Prinja

Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting pp. 623-623

Sara Stafford, Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis and Aiden Liu

Volume 20, issue 3, 2022

How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG? pp. 287-290

Charalabos-Markos Dintsios and Nadja Chernyak

Should Hungary Pay More for a QALY Gain than Higher-Income Western European Countries? pp. 291-303

Sándor Kovács, Bertalan Németh, Dalma Erdősi, Valentin Brodszky, Imre Boncz, Zoltán Kaló and Antal Zemplényi

Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance pp. 305-313

Ruth Louise Poole, Megan Dale, Helen Morgan, Tosin Oladapo, Rebecca Brookfield and Rhys Morris

A Systematic Review on Economic Evaluation Studies of Diagnostic and Therapeutic Interventions in the Middle East and North Africa pp. 315-335

Mouaddh Abdulmalik Nagi, Pramitha Esha Nirmala Dewi, Montarat Thavorncharoensap and Sermsiri Sangroongruangsri

Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries pp. 337-349

Laura Vallejo-Torres, Borja García-Lorenzo, Laura Catherine Edney, Niek Stadhouders, Ijeoma Edoka, Iván Castilla-Rodríguez, Lidia García-Pérez, Renata Linertová, Cristina Valcárcel-Nazco and Jonathan Karnon

Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review pp. 351-370

Jiayu Shi, Kenan Fan, Lei Yan, Zijuan Fan, Fei Li, Guishan Wang, Haifeng Liu, Peidong Liu, Hongmei Yu, Jiao Jiao Li and Bin Wang

Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India pp. 371-381

V. Srinivasan, David E. Bloom and Alex Khoury

Exploring EQ-5D-Y-3L Experience-Based VAS Values Derived Among Adolescents pp. 383-393

Mimmi Åström, Ola Rolfson and Kristina Burström

Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries pp. 395-404

Siyu Ma, Tara A. Lavelle, Daniel A. Ollendorf and Pei-Jung Lin

How Did the Affordable Care Act Affect Risky Health Behaviors? pp. 405-416

Cagdas Agirdas

Scope Issue in Contingent Valuation Studies of the COVID-19 Vaccine: The Case of China pp. 417-429

Jianhong Xiao, Yihui Wu, Min Wang and Zegang Ma

Cost-effectiveness Analysis of the Dental RECUR Pragmatic Randomized Controlled Trial: Evaluating a Goal-oriented Talking Intervention to Prevent Reoccurrence of Dental Caries in Children pp. 431-445

Ezeofor Victory, Edwards T. Rhiannon, Burnside Girvan, Adair Pauline and Pine M. Cynthia

Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be? pp. 447-449

Howard Thom

Correction to: Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be? pp. 451-451

Howard Thom

Volume 20, issue 2, 2022

Integrated Care in Europe: Time to Get it Together? pp. 145-147

Livio Garattini, Marco Badinella Martini and Alessandro Nobili

From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R pp. 149-158

Yiqiao Xin, Ewan Gray, Jose Antonio Robles-Zurita, Houra Haghpanahan, Robert Heggie, Ciaran Kohli-Lynch, Andrew Briggs, David A. McAllister, Kenny D. Lawson and Jim Lewsey

Episcissors-60 for Mediolateral Episiotomy: Evaluation of Clinical and Economic Evidence to Inform NICE Medical Technologies Guidance pp. 159-169

Susan O’Connell, Megan Dale, Helen Morgan, Bernice Dillon, Andrew Cleves, Rhys Morris and Grace Carolan-Rees

Population-Based Testing for Undiagnosed Hepatitis C: A Systematic Review of Economic Evaluations pp. 171-183

Paul G. Carty, Christopher G. Fawsitt, Paddy Gillespie, Patricia Harrington, Michelle O’Neill, Susan M. Smith, Conor Teljeur and Mairin Ryan

The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations pp. 185-198

Siyuan Liu, Paul J. Veugelers, Chunhao Liu and Arto Ohinmaa

The Effect of Price Changes and Teaspoon Labelling on Intention to Purchase Sugar-Sweetened Beverages: A Discrete Choice Experiment pp. 199-212

Vinh Vo, K.-H. Nguyen, J. A. Whitty and Tracy A. Comans

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations pp. 213-221

Don Husereau, Michael Drummond, Federico Augustovski, Esther Bekker-Grob, Andrew H. Briggs, Chris Carswell, Lisa Caulley, Nathorn Chaiyakunapruk, Dan Greenberg, Elizabeth Loder, Josephine Mauskopf, C. Daniel Mullins, Stavros Petrou, Raoh-Fang Pwu and Sophie Staniszewska

The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis pp. 223-233

Vincenzo Alfano

Are Medical Devices Cost-Effective? pp. 235-241

James D. Chambers, Madison C. Silver, Flora C. Berklein, Joshua T. Cohen and Peter J. Neumann

Effect of Competition on Generic Drug Prices pp. 243-253

Nguyen Xuan Nguyen, Steven H. Sheingold, Wafa Tarazi and Arielle Bosworth

Willingness to Pay for National Health Insurance: A Contingent Valuation Study Among Patients Visiting Public Hospitals in Melaka, Malaysia pp. 255-267

Robin Tiow Heng Tan, Siti Zaleha Abdul Rasid, Wan Khairuzzaman Wan Ismail, Janiza Tobechan, Edwin Tiow Yong Tan, Alia Natasha Yusof and Jia Hui Low

Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study pp. 269-282

Caroline S. Clarke, Larisa Duffy, Glyn Lewis, Nick Freemantle, Simon Gilbody, Tony Kendrick, David Kessler, Michael King, Paul Lanham, Derelie Mangin, Michael Moore, Irwin Nazareth, Nicola Wiles, Louise Marston and Rachael Maree Hunter

Correction to: Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study pp. 283-283

Caroline S. Clarke, Larisa Duffy, Glyn Lewis, Nick Freemantle, Simon Gilbody, Tony Kendrick, David Kessler, Michael King, Paul Lanham, Derelie Mangin, Michael Moore, Irwin Nazareth, Nicola Wiles, Louise Marston and Rachael Maree Hunter

Correction to: The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations pp. 285-285

Siyuan Liu, Paul J. Veugelers, Chunhao Liu and Arto Ohinmaa

Volume 20, issue 1, 2022

Financial Incentives in the Path to Recovery from the COVID-19 Pandemic pp. 5-8

Afschin Gandjour

Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers pp. 9-11

Jonathan Karnon, Andrew Partington and Hossein Afzali

Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment pp. 13-18

James Lomas, Jessica Ochalek and Rita Faria

Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review pp. 19-33

Margherita Neri, Patricia Cubi-Molla and Graham Cookson

Quality of Health Economic Evaluations in Mainland China: A Comparison of Peer-Reviewed Articles in Chinese and in English pp. 35-54

Jiehua Cheng, Yu Zhang, Ailin Zhong, Miao Tian, Guanyang Zou, Xiaping Chen, Hongxing Yu, Fujian Song and Shangcheng Zhou

Is There Broad-Based Support in High-Income Countries for COVID-19 Vaccine Donation? Evidence from Seven Countries pp. 55-65

Laurence Roope, Adrian Barnett, Paolo Candio, Mara Violato, Raymond Duch and Philip M. Clarke

Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America pp. 67-77

Daniela Moye-Holz and S. Vogler

Economic Evaluation of an Intervention Designed to Reduce Bullying in Australian Schools pp. 79-89

Amarzaya Jadambaa, Nicholas Graves, Donna Cross, Rosana Pacella, Hannah J. Thomas, James G. Scott, Qinglu Cheng and David Brain

Costs and Cost-Effectiveness of User-Testing of Health Professionals’ Guidelines to Reduce the Frequency of Intravenous Medicines Administration Errors by Nurses in the United Kingdom: A Probabilistic Model Based on Voriconazole Administration pp. 91-104

Matthew D. Jones, Bryony Dean Franklin, D. K. Raynor, Howard Thom, Margaret C. Watson and Rebecca Kandiyali

Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward pp. 105-117

Eleanor Bell, Margherita Neri and Lotte Steuten

Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores pp. 119-131

Aurelie Meunier, Alexandra Soare, Helene Chevrou-Severac, Karl-Johan Myren, Tatsunori Murata and Louise Longworth

Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis pp. 133-143

Andrea Marcellusi, Claudia Simonelli, Francesco Saverio Mennini and Loreta A. Kondili